(Reuters)—Drugmaker Regeneron Pharmaceuticals Inc. said on Monday its experimental drug to treat moderate to severe osteoarthritis pain was successful in a late-stage study. The drug, fasinumab, was tested on 421 patients with a history of inadequate pain relief or intolerance to current painkillers. Fasinumab binds to nerve growth factor (NGF) proteins and block their activity,…
France Gets G7 to Discuss Global Regulation of Medicine Prices
PARIS (Reuters)—France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable, three sources told Reuters. President Francois Hollande said in March he would push for the international regulation of drugs prices when he meets…
Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
NEW YORK (Reuters Health)—The anti-interleukin (IL)-12/IL-23 monoclonal antibody ustekinumab improves signs and symptoms of spondylitis in patients with psoriatic arthritis, according to a post-hoc analysis of data from the PSUMMIT-1 and PSUMMIT-2 trials. “This treatment did seem to have a benefit on axial symptoms,” Dr. Arthur Kavanaugh from the University of California San Diego, La…
Researchers Work to Untangle the Relationship Between Blood Lipids, Bone Health & Diet
A recent editorial examined research findings on how low levels of high-density lipoprotein (HDL) in the blood affect bone health, resulting in cartilage dysfunction and the development of osteoarthritis (OA). Authors note that a high-fat diet in mice with HDL deficiency resulted in OA development; thus, they conclude that in patients with metabolic syndrome, HDL may have a causative relationship to OA…
Anthem CEO Backs Obamacare Insurance Exchanges & Sees Possible Growth
(Reuters)—Health insurer Anthem Inc. on Wednesday said the Obamacare individual insurance exchanges are not as profitable as it originally expected, but it is not planning to exit like competitor UnitedHealth Group. Anthem Chief Executive Officer Joseph Swedish said the company had picked up more exchange customers than it expected during the first quarter and that…
From the Expert: Dr. Anne Bass Addresses Fellowship Training in Rheumatology
As the need for specialists increases, the Rheumatology Fellowship Program at HHS seeks to grow the number of practicing rheumatologists. Program Director Anne Bass, MD, discusses the program’s ideas behind funding rheumatology fellowships and the challenges of attracting medical students to the field…
Patients with Mental Illness Fare Worse after Hip Surgery
(Reuters Health)—People with psychiatric illnesses are more likely to have complications after hip replacement surgery, according to a recent analysis. This added risk is something doctors and patients should discuss in advance, the study team writes in The Journal of Arthroplasty, March 17. Previous studies have linked depression and other mental illnesses to greater complications…
Ryan Wants to End Obamacare Cost Protections for Sick Consumers
WASHINGTON (Reuters)—U.S. House of Representatives Speaker Paul Ryan (R-Wis.) called on Wednesday for an end to Obamacare‘s financial protections for people with serious medical conditions, saying these consumers should be placed in state high-risk pools. In election-year remarks that could shed light on an expected Republican healthcare alternative, Ryan said existing federal policy that prevents…
2015 Treatment Recommendations for Psoriatic Arthritis
Psoriatic arthritis (PsA) is remarkably diverse in presentation and course. To assist clinicians in its management, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published treatment recommendations in 2009 based on a systematic evidence review. To be clinically relevant, such recommendations must be dynamic, and significant developments in PsA pathophysiology and disease assessment, particularly regarding the important contribution of comorbidities coupled with major therapeutic advances, necessitated an update of the GRAPPA recommendations…
Triple Therapy with Methotrexate Effective, Cheaper in RA
NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…
- « Previous Page
- 1
- …
- 506
- 507
- 508
- 509
- 510
- …
- 815
- Next Page »